|
Quesada MP, Garcia-Bernal D, Pastor D, Estirado A, Blanquer M, Garcia-Hernandez AM, Moraleda JM, Martinez S. Safety and Biodistribution of Human Bone Marrow-Derived Mesenchymal Stromal Cells Injected Intrathecally in Non-Obese Diabetic Severe Combined Immunodeficiency Mice: Preclinical Study. Tissue Eng Regen Med. 2019 Jul 26;16(5):525-538. doi: 10.1007/s13770-019-00202-1. eCollection 2019 Oct. PubMed PMID: 31624707; PubMed Central PMCID: PMC6778571.
AÑO: 2019; IF: 2.374
|
31624707
|
Rosinol L, Oriol A, Rios R, Sureda A, Blanchard MJ, Hernandez MT, Martinez-Martinez R, Moraleda JM, Jarque I, Bargay J, Gironella M, de Arriba F, Palomera L, Gonzalez-Montes Y, Marti JM, Krsnik I, Arguinano JM, Gonzalez ME, Gonzalez AP, Casado LF, Lopez-Anglada L, Paiva B, Mateos MV, San Miguel JF, Lahuerta JJ, Blade J. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. Blood. 2019 Oct 17;134(16):1337-1345. doi: 10.1182/blood.2019000241. PubMed PMID: 31484647; PubMed Central PMCID: PMC6888142.
AÑO: 2019; IF: 17.794
|
|
Mirones I, Moreno L, Patino-Garcia A, Lizeaga G, Moraleda JM, Toribio ML, Perez-Martinez A; Grupo de Inmunoterapia y Terapias Avanzadas de la Sociedad Espanola de Hematologia y Oncologia Pediatricas; Grupo de Inmunoterapia y Terapias Avanzadas de la Sociedad Espanola de Hematologia y Oncologia Pediatricas. [Immunotherapy with CAR-T cells in paediatric haematology-oncology]. An Pediatr (Engl Ed). 2020 Jul;93(1):59.e1-59.e10. doi: 10.1016/j.anpedi.2019.12.014. Epub 2020 Feb 24. Spanish. PubMed PMID: 32107177.
AÑO: 2020; IF: 1.5
|
|
Esteban T, Atucha NM, Moraleda JM, Garcia-Estan J, Insausti CL, Moraleda-Deleyto J. Chronic model of tympanic perforation in rats with mitomycin C and dexamethasone. J Otol. 2019 Mar;14(1):12-16. doi: 10.1016/j.joto.2018.11.002. Epub 2018 Nov 10. Erratum In: J Otol. 2020 Dec;15(4):180. PubMed PMID: 30936896; PubMed Central PMCID: PMC6424699.
AÑO: 2019
|
|
Soria-Juan B, Escacena N, Capilla-Gonzalez V, Aguilera Y, Llanos L, Tejedo JR, Bedoya FJ, Juan V, De la Cuesta A, Ruiz-Salmeron R, Andreu E, Grochowicz L, Prosper F, Sanchez-Guijo F, Lozano FS, Miralles M, Del Rio-Sola L, Castellanos G, Moraleda JM, Sackstein R, Garcia-Arranz M, Garcia-Olmo D, Martin F, Hmadcha A, Soria B; Collaborative Working Group "Noma Project Team". Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus. Front Immunol. 2019 Jun 4;10:1151. doi: 10.3389/fimmu.2019.01151. eCollection 2019. Erratum In: Front Immunol. 2020 Sep 02;11:2029. PubMed PMID: 31231366; PubMed Central PMCID: PMC6558400.
AÑO: 2019; IF: 5.085
|